More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants
- PMID: 37119830
- PMCID: PMC10132782
- DOI: 10.1016/S1473-3099(23)00274-8
More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants
Conflict of interest statement
PM and WB-E declare funding to their institution from Gilead for participation as site co-investigators for a completed clinical trial.
Comment on
-
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.Lancet Infect Dis. 2023 May;23(5):527-528. doi: 10.1016/S1473-3099(23)00181-0. Epub 2023 Mar 29. Lancet Infect Dis. 2023. PMID: 37003292 Free PMC article. No abstract available.
References
-
- Branche AR, Rouphael NG, Diemert DJ, et al. SARS-CoV-2 variant vaccine boosters trial: preliminary analyses. medRxiv. 2022 doi: 10.1101/2022.07.12.22277336. published online July 15. (preprint). - DOI
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
